InVisionFirst®-Lung offers timely results delivered within 7 calendar days from blood draw and 98% concordance with tissue biopsy to help support the prognosis and therapeutic decisions in patients diagnosed with advanced non-small cell lung cancer (NSCLC).

This is a ctDNA NGS liquid biopsy that now tests 37 genes relevant to the care of advanced NSCLC patients.

We now offer Mobile Phlebotomy Services

FIND OUT MORE

Addressing Fusions in NSCLC

  • RET Fusion

    RET fusion is a predictive biomarker used in cabozantinib and vandetanib for patients with NSCLC.

    Based on the presence of RET fusion, there are currently 2 NCCN guidelines that support its use as a targeted biomarker-directed therapy, with NSCLC and thyroid gland medullary carcinoma having the most therapies targeted against RET fusion.

  • NTRK1 Fusion

    The NTRK1 gene plays a role in developing and maintaining the nervous system. It is also a predictive biomarker used in larotrectinib. Gene fusions of NTRK can lead to the development of abnormal proteins that may cause cancer cell growth.

    Mutations to this gene have been found in patients with lung adenocarcinoma, colorectal cancer, papillary thyroid cancer, glioblastoma multiforme and in cholangiocarcinoma. Malignant tumors have the most therapies targeted against NTRK1 fusion.

  • ALK Fusion

    ALK rearrangements have been identified in colon, ovarian and non-small cell lung cancers where ALK fusions comprise approximately RET STK11 3-5% of lung tumors.

    Although ALK fusion products have been shown to confer sensitivity to ALK tyrosine kinase inhibitors, emergence of mutations in the ALK kinase domain have been reported to confer resistance to treatment.

  • ROS1 Fusion

    ROS1 gene rearrangement fusion events haVve been identified in approximately 2% of lung cancer cases, and have been detected in other cancers including ovarian carcinoma, sarcoma and cholangiocarcinomas.

    Harboring a ROS1 mutation may confer increased sensitivity to ROS1 inhibitors.

    Somatic mutations have also been identified that may drive resistance or sensitivity to ROS1 inhibitors.

In the US, InVisionFirst®-Lung is now covered for Medicare and United Health Care (UHC) patients with advanced (Stage IIIB/IV) NSCLC. See full details here.

A Simple, Straightforward Process

Our samples are easily collected, accurately tested, and results are delivered within 7 calendar days from blood draw through a secure clinician portal.

The report also includes all genetic alterations and corresponding recommended therapeutics, such as assessment of predicted response to treatments and available to currently enrolling clinical trials. This report can be exported or added easily to almost any electronic health record (EHR).

Advocate for Your Patients

We are focused on making a difference in the lives of lung cancer patients by evolving our technology based on the feedback from all our valued customers.

Our InVisionFirst®-Lung test brings high sensitivity and specificity to drive appropriate treatment choice in advanced lung cancer patients.

GET STARTED